Clinical trials
Resectable Intrahepatic Cholangiocarcinoma clinical trials
Below are recruiting resectable intrahepatic cholangiocarcinoma clinical trials, each written for real people, not researchers. We’re tracking 48 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05265208RecruitingPhase 2
Radiation plus chemo after liver surgery for bile duct cancer
This trial studies giving a special internal radiation treatment along with capecitabine (a chemotherapy) for liver cancer related to bile ducts, after planned surgical removal. It may help improve control of the cancer in cases where surgeons think the edges of the removed tumor may be too close.
Rennes, Brittany RegionAges 18 years+ - NCT06462742Recruiting
Microwave ablation vs. surgery for intrahepatic cholangiocarcinoma
This trial compares two treatments for a liver cancer called intrahepatic cholangiocarcinoma—surgery to remove the tumor versus microwave ablation, which uses heat to destroy cancer cells. It tests if ablation works as well as surgery for people with small tumors that haven't spread.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07640048Recruiting
Adjuvant therapy after surgery for high-risk bile duct cancer
This study tests additional treatment given after surgery to remove high-risk intrahepatic cholangiocarcinoma (a type of bile duct cancer). The goal is to reduce the chance the cancer comes back and improve survival in patients whose tumors had concerning features.
BeijingAges 18 years+ - NCT06859684RecruitingPhase 2
Triple therapy for advanced bile duct cancer of the liver
This trial tests a combination of three treatments for people with advanced bile duct cancer that cannot be removed by surgery or has spread. The treatments include a chemotherapy infusion directly into the liver artery (HAIC), an immunotherapy drug (durvalumab), and a targeted therapy pill (lenvatinib). It aims to see if this triple therapy can shrink or control the cancer better than standard treatments.
Chengdu, SichuanAges 18–75 - NCT06487663Recruiting
TACE plus immunotherapy for untreated liver cancer
This study tests combining TACE (a procedure to block the tumor's blood supply) with immunotherapy drugs for liver cancer that has not spread outside the liver. It is for people who have not had any prior treatment for their liver cancer and are healthy enough for TACE.
TianjinAges 18–75 - NCT06607276RecruitingPhase 2
Adjuvant adebrelimab and capecitabine for high-risk bile duct cancer
This trial is for people with bile duct cancer who have had surgery to remove all visible cancer but are at high risk of it coming back. It tests whether adding two medications — adebrelimab (an immunotherapy) and capecitabine (a chemotherapy pill) — after surgery can help prevent the cancer from returning.
Nanjing, JiangsuAges 18–75 - NCT04993131Recruiting
Liver transplant for non-surgical bile duct cancer
This trial studies liver transplantation for people with a specific type of bile duct cancer near the liver that cannot be safely removed by surgery. It aims to improve outcomes by offering a transplant after the cancer responds to chemotherapy and spread has been ruled out on scans.
OsloAges 18 years+ - NCT06860477RecruitingPhase 2
Freezing therapy plus targeted drugs vs. chemotherapy for advanced bile duct cancer
This trial tests whether a combination of cryoablation (freezing tumors) and two drugs (lenvatinib and tislelizumab) works better than a standard chemotherapy regimen (FOLFOX) for people with advanced intrahepatic cholangiocarcinoma (a type of bile duct cancer in the liver) that has not responded to or has stopped responding to one prior therapy.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT03364530RecruitingPhase 2
Liver artery chemotherapy for non-surgical bile duct cancer
This trial tests delivering two chemotherapy medicines directly into the liver’s artery in people with bile duct cancer inside the liver that cannot be removed with curative surgery. It aims to control the cancer after first-line treatment and see how well this targeted approach works.
AmiensAges 18 years+ - NCT04891289RecruitingPhase 2
Gemcitabine and oxaliplatin with a chemotherapy pump for bile duct cancer
This Phase 2 study tests gemcitabine plus oxaliplatin chemotherapy, and whether adding a chemotherapy pump (with floxuridine and dexamethasone) delivered to the liver improves outcomes. It is for people whose intrahepatic cholangiocarcinoma cannot be removed with surgery.
Bethesda, MarylandAges 18 years+ - NCT05557578RecruitingPhase 2
New drug before surgery for resectable bile duct cancer
This Phase 2 trial tests a “neoadjuvant” (before-surgery) treatment for resectable intrahepatic cholangiocarcinoma (bile duct cancer in the liver) that has higher risk of coming back. It aims to shrink or control the cancer before the operation, and to see if patients can safely undergo surgery afterward.
Hangzhou, ZhejiangAges 18–75 - NCT06862934Recruiting
Liver transplant for bile duct cancer that can't be removed
This study tests if a liver transplant can help people with a type of bile duct cancer (intrahepatic cholangiocarcinoma) that cannot be surgically removed. It is for patients whose cancer has been stable for at least 6 months after initial treatments.
Milan, MilanAges 18–70 - NCT07760038Recruiting
Phycocyanin for liver protection before partial liver removal
This trial tests whether phycocyanin, a natural supplement, can protect the liver before and after surgery to remove part of the liver. It is for people with a type of bile duct cancer who are already getting chemotherapy and other treatments before surgery.
Hangzhou, ZhejiangAges 18–75 - NCT05422690RecruitingPhase 2
Treating bile duct cancer with chemo plus Y-90 radiation
This Phase 2 study tests whether combining chemotherapy (gemcitabine and cisplatin) and an immunotherapy drug (durvalumab) with targeted Y-90 radiation can shrink inoperable intrahepatic cholangiocarcinoma tumors. It’s looking for better tumor shrinking and improved cancer control.
Fairfax, VirginiaAges 18 years+ - NCT05010681RecruitingPhase 2
Lenvatinib plus immunotherapy after prior liver cancer treatment
This Phase 2 trial tests lenvatinib combined with the immunotherapy drug sintilimab in people with advanced liver cancer who got worse after prior PD-1/PD-L1 treatment. It aims to slow cancer growth and improve outcomes after immune therapy hasn’t worked.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT05342194RecruitingPhase 3
Testing an immunotherapy plus chemo for advanced bile duct cancer
This Phase 3 study tests whether toripalimab (an immunotherapy) combined with lenvatinib and chemotherapy works better than standard treatment for advanced intrahepatic cholangiocarcinoma. It aims to help people live longer and/or control the cancer more effectively.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06505486Recruiting
Combination therapy for large inoperable bile duct cancer
This trial looks at a combined treatment for a large, inoperable type of liver cancer (intrahepatic cholangiocarcinoma). It uses chemotherapy delivered directly into the liver, plus a targeted pill (lenvatinib) and an immunotherapy drug (PD-1 inhibitor) to try shrink the tumor and improve outcomes.
Guangzhou, GuangzhouAges 18–70 - NCT06583993RecruitingEarly Phase 1
Gene Therapy for Advanced Bile Duct Cancer
This early-phase trial tests a new kind of gene therapy (called HNF4α srRNA) given through a vein for people with advanced intrahepatic cholangiocarcinoma, a type of liver cancer that has stopped responding to standard chemotherapy. The goal is to see if it is safe and if it can help slow or stop the cancer.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06735560Recruiting
PET scan with a tracer for liver, bile duct, or neuroendocrine tumors
This trial uses a special PET scan tracer (zirconium-labelled girentuximab) to see if it can find and track certain liver, bile duct, and pancreatic/intestinal neuroendocrine tumors. It may help doctors better understand your cancer and guide treatment decisions.
NantesAges 18 years+ - NCT06925516RecruitingPhase 2
Apatinib plus immunotherapy and chemo for unresectable bile duct cancer
This study tests a combination of two drugs (apatinib and adebrelimab) with standard chemotherapy for people with bile duct cancer that cannot be removed surgically. The goal is to see if this combination works better than chemotherapy alone.
Guangzhou, GuangdongAges 18–75 - NCT07101237Recruiting
Precision diagnosis and treatment study for liver cancer
This study aims to improve how doctors diagnose and treat liver cancer by combining advanced imaging tests and genetic analysis. It may help in choosing the most effective treatment for each person.
BeijingAges 18–70 - NCT07201519RecruitingPhase 2
Chemo infusion for liver cancer using a hybrid care model
This trial tests a special type of chemotherapy (hepatic artery infusion) for people with cancers that have spread to the liver, such as colorectal cancer or bile duct cancer (intrahepatic cholangiocarcinoma). It studies whether delivering this treatment partly at a community center and partly at a university hospital is safe and feasible.
Lexington, KentuckyAges 18–99 - NCT05978609RecruitingPhase 2
Testing cadonilimab plus chemotherapy for advanced bile duct cancer
This trial tests a new combination therapy for people with advanced bile duct or gallbladder cancer that can't be removed by surgery. It combines a drug called cadonilimab with standard chemotherapy to see if it works better than chemotherapy alone.
Chengdu, SichuanAges 18–75 - NCT06037980RecruitingPhase 2/Phase 3
Chemotherapy before surgery for high-risk bile duct cancer
This trial tests whether receiving chemotherapy (cisplatin, gemcitabine, and nab-paclitaxel) before surgery can improve outcomes for people with high-risk bile duct or gallbladder cancer. It compares this approach to going straight to surgery.
AnconaAges 18–75
Hear when a new Resectable Intrahepatic Cholangiocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for resectable intrahepatic cholangiocarcinoma?
- Yes. Clin2 currently lists 48 recruiting resectable intrahepatic cholangiocarcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a resectable intrahepatic cholangiocarcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a resectable intrahepatic cholangiocarcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.